The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
The clinical significance and prognostic value of CD10 in de novo diffuse large B-cell lymphoma (DLBCL) is largely unknown. We retrospectively studied 19 men and 9 women based on the following criteria: (1) DLBCL with no evidence of concomitant or antecedent follicular lymphoma; (2) available flow cytometric immunophenotyping data, including CD10 status; (3) older than 15 years; (4) specific exclusion of high-grade, Burkitt-like lymphoma; and (5) exclusion of primary cutaneous DLBCL. When available, clinical data at diagnosis, including components of the international prognostic index, were reviewed. Eleven cases were CD10+, and 17 were CD10-. There was no significant difference between the CD10+ and CD10- groups in age, sex, stage, performance status, extranodal involvement, or serum lactate dehydrogenase levels at diagnosis. However, in the 26 cases for which follow-up data were available, the CD10+ group displayed a shorter overall survival than the CD10- group (8 vs 30 months). Although the clinical findings at diagnosis are similar in CD10+ and CD10- DLBCL, CD10 expression is associated with shortened overall survival. Therefore, our data suggest CD10 expression may have prognostic importance in adults with de novo DLBCL.
Uherova
P
P
Department of Pathology, University of Michigan Medical School, Ann Arbor, USA.
Ross
C W
CW
Schnitzer
B
B
Singleton
T P
TP
Finn
W G
WG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000096:biosynthesis*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
D015260:Neprilysin